-
Mashup Score: 5Impact of disease stage and MRD treatment on outcomes in patients with NPM1-mutated AML proceeding to allo-HSCT - 4 day(s) ago
Here, we summarize the outcomes of patients with NPM1-mutated AML in relation to their disease stage at the time of allo-HSCT presented by Bug at the 50th Annual Meeting of the EBMT.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Allo-HSCT vs consolidation therapy to improve leukemia-free survival in elderly patients with AML. - 9 day(s) ago
Here, we summarize a presentation by Niederwieser from the 50th Annual Meeting of the EBMT investigating whether allo-HSCT improves leukemia free survival vs non allo-HSCT consolidation therapy in elderly patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Impact of molecular ontogeny on outcomes in patients with newly diagnosed AML treated with HMA + venetoclax - 17 day(s) ago
Here, we summarize a study investigating whether secondary molecular ontogeny implies adverse risk in patients with AML treated with HMA + venetoclax vs HMA monotherapy.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18HMA + venetoclax in adults with TP53-mutated AML - 19 day(s) ago
Here, we summarize an article by Badar, et al. in Blood Cancer Journal comparing venetoclax + HMA with HMA-based therapy alone for newly diagnosed TP53-mutated AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3IDHENTIFY trial: Impact of mutational burden and pattern on outcomes in patients with R/R IDH2-mutated AML - 23 day(s) ago
Here, we summarize a post hoc analysis of the IDHENTIFY trial investigating the molecular characteristics and prognostic impact of co-occurring mutations in patients with R/R IDH2-mutated AML and treated with enasidenib.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3The Pre-MEASURE study: How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML? - 25 day(s) ago
The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 MRD affect posttransplant outcomes in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Low dose azacitidine + venetoclax as maintenance therapy for patients with AML in remission - 1 month(s) ago
Here, we summarize a phase II study investigating the safety and efficacy of low-dose azacitidine + venetoclax as maintenance therapy in patients with acute myeloid leukemia in remission after either intensive or low-intensity induction.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
On April 30, 2024, the U.S. FDA granted Orphan Drug Designation to IGNK001, an investigational allogeneic NK cell therapy derived from healthy donors, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Here, we summarize results from a pilot study by Wang et al. investigating the safety and tolerability of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 33Gemtuzumab ozogamicin plus 7 + 3 induction therapy in patients with intermediate-risk ND AML - 1 month(s) ago
Here, we summarize a real-world retrospective analysis by Awada et al. investigating whether the addition of gemtuzumab ozogamicin to intensive 7 + 3 induction therapy is beneficial in patients with intermediate-risk ND AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
What is the impact of disease stage and MRD positivity on survival outcomes in patients with NPM1-mutated AML at the time of allo-HSCT? Read our summary of a presentation from #EBMT24 to learn more: https://t.co/L8yhhNohSj #AMLsm #leusm #leukemia #MedicalEducation https://t.co/gBiOOaNtu3